|
1
|
Akiyama M, Yamada O, Agawa M, Yuza Y,
Yanagisawa T, Eto Y and Yamada H: Effects of prednisolone on
specifically expressed genes in pediatric acute B-lymphoblastic
leukemia. J Pediatr Hematol Oncol. 30:313–316. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Luan C, Yang Z and Chen B: The functional
role of microRNA in acute lymphoblastic leukemia: Relevance for
diagnosis, differential diagnosis, prognosis, and therapy. Onco
Targets Ther. 8:2903–2914. 2015.PubMed/NCBI
|
|
3
|
Fang M, Becker PS, Linenberger M, Eaton
KD, Appelbaum FR, Dreyer Z, Airewele G, Redell M, Lopez-Terrada D,
Patel A, et al: Adult low-hypodiploid acute B-Lymphoblastic
leukemia with IKZF3 deletion and TP53 mutation: Comparison with
pediatric patients. Am J Clin Pathol. 144:263–270. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Severson EA, Vergilio JA, Gay LM, Daniel
S, Hemmerich AC, Elvin JA, Britt N, Nahas M, Cohen MB, Brown C, et
al: Genomic landscape of adult and pediatric BCR-ABL1-like
b-lymphoblastic leukemia using parallel DNA and RNA sequencing.
Oncologist. 24:372–374. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Evensen NA, Madhusoodhan PP, Meyer J,
Saliba J, Chowdhury A, Araten DJ, Nersting J, Bhatla T, Vincent TL,
Teachey D, et al: MSH6 haploinsufficiency at relapse contributes to
the development of thiopurine resistance in pediatric
B-lymphoblastic leukemia. Haematologica. 103:830–839. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Oberley MJ, Li S, Orgel E, Phei Wee C,
Hagiya A and O'Gorman MRG: Clinical significance of isolated
myeloperoxidase expression in pediatric B-Lymphoblastic leukemia.
Am J Clin Pathol. 147:374–381. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bennett JM, Catovsky D, Daniel MT,
Flandrin G, Galton DA, Gralnick HR and Sultan C: Proposals for the
classification of the acute leukaemias. French-American-British
(FAB) co-operative group. Br J Haematol. 33:451–458. 1976.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Crist WM, Furman W and Strother D.and Pui
CH: Acute lymphocytic leukemia in childhood: Immunologic marker,
cytogenetic, and molecular studies. South Med J. 80:841–847. 1987.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Subspecialty Group of Hematology and The
Society of Pediatrics, Chinese Medical Association, . Summary of
the 16th national conference of pediatric hematology. Zhonghua Er
Ke Za Zhi (Chinese). 51:76–77. 2013.
|
|
10
|
Douet-Guilbert N, Chauveau A, Gueganic N,
Guillerm G, Tous C, Le Bris MJ, Basinko A, Morel F, Ugo V and De
Braekeleer M: Acute myeloid leukaemia (FAB AML-M4Eo) with cryptic
insertion of cbfb resulting in cbfb-Myh11 fusion. Hematol Oncol.
35:385–389. 2017. View
Article : Google Scholar : PubMed/NCBI
|
|
11
|
Canaani J, Beohou E, Labopin M, Socié G,
Huynh A, Volin L, Cornelissen J, Milpied N, Gedde-Dahl T, Deconinck
E, et al: Impact of FAB classification on predicting outcome in
acute myeloid leukemia, not otherwise specified, patients
undergoing allogeneic stem cell transplantation in CR1: An analysis
of 1690 patients from the acute leukemia working party of EBMT. Am
J Hematol. 92:344–350. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Balatti V, Tomasello L, Rassenti LZ,
Veneziano D, Nigita G, Wang HY, Thorson JA, Kipps TJ, Pekarsky Y,
Croce CM, et al: miR-125a and miR-34a expression predicts Richter
syndrome in chronic lymphocytic leukemia patients. Blood.
132:2179–2182. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
El-Khazragy N, Elshimy AA, Hassan SS,
Matbouly S, Safwat G, Zannoun M and Riad RA: Dysregulation of
miR-125b predicts poor response to therapy in pediatric acute
lymphoblastic leukemia. J Cell Biochem. 2–Nov;2018.(Epub ahead of
print).
|
|
14
|
Gutierrez-Camino A, Umerez M,
Martin-Guerrero I, García de Andoin N, Santos B, Sastre A,
Echebarria-Barona A, Astigarraga I, Navajas A and Garcia-Orad A:
Mir-pharmacogenetics of Vincristine and peripheral neurotoxicity in
childhood B-cell acute lymphoblastic leukemia. Pharmacogenomics J.
18:704–712. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
He Z, Liao Z, Chen S, Li B, Yu Z, Luo G,
Yang L, Zeng C and Li Y: Downregulated miR-17, miR-29c, miR-92a and
miR-214 may be related to BCL11B overexpression in T cell acute
lymphoblastic leukemia. Asia Pac J Clin Oncol. 14:e259–e265. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hong Z, Zhang R and Qi H: Diagnostic and
prognostic relevance of serum miR-195 in pediatric acute myeloid
leukemia. Cancer Biomark. 21:269–275. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Huang Y, Zou Y, Lin L, Ma X and Chen H:
Identification of serum miR-34a as a potential biomarker in acute
myeloid leukemia. Cancer Biomark. 22:799–805. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Jiang Q, Lu X, Huang P, Gao C, Zhao X,
Xing T, Li G, Bao S and Zheng H: Expression of miR-652-3p and
effect on apoptosis and drug sensitivity in pediatric acute
lymphoblastic leukemia. Biomed Res Int. 2018:57246862018.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zang Y, Yu R, Bai Y and Chen X: MicroRNA-9
suppresses cancer proliferation and cell cycle progression in acute
lymphoblastic leukemia with inverse association of neuropilin-1. J
Cell Biochem. 119:6604–6613. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Rokah OH, Granot G, Ovcharenko A, Modai S,
Pasmanik-Chor M, Toren A, Shomron N and Shpilberg O: Downregulation
of miR-31, miR-155, and miR-564 in chronic myeloid leukemia cells.
PLoS One. 7:e355012012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yamagishi M, Nakano K, Miyake A, Yamochi
T, Kagami Y, Tsutsumi A, Matsuda Y, Sato-Otsubo A, Muto S,
Utsunomiya A, et al: Polycomb-mediated loss of miR-31 activates
NIK-dependent NF-κB pathway in adult T cell leukemia and other
cancers. Cancer Cell. 21:121–135. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wood B, Wu D, Crossley B, Dai Y,
Williamson D, Gawad C, Borowitz MJ, Devidas M, Maloney KW, Larsen
E, et al: Measurable residual disease detection by high-throughput
sequencing improves risk stratification for pediatric B-ALL. Blood.
131:1350–1359. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Moricke A, Reiter A, Zimmermann M, Gadner
H, Stanulla M, Dördelmann M, Löning L, Beier R, Ludwig WD, Ratei R,
et al: Risk-adjusted therapy of acute lymphoblastic leukemia can
decrease treatment burden and improve survival: Treatment results
of 2169 unselected pediatric and adolescent patients enrolled in
the trial ALL-BFM 95. Blood. 111:4477–4489. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
